Radium-223 dichloride in clinical practice: a review
L Florimonte, L Dellavedova, LS Maffioli - European journal of nuclear …, 2016 - Springer
The onset of skeletal metastases is typical of advanced-stage prostate cancer and requires a
multidisciplinary approach to alleviate bone pain and try to delay disease progression. The …
multidisciplinary approach to alleviate bone pain and try to delay disease progression. The …
[HTML][HTML] Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
K Yoshida, T Kaneta, S Takano, M Sugiura… - Annals of nuclear …, 2016 - Springer
Objective This open-label, non-randomized, phase I study examined the pharmacokinetics
(PK) and radiation dosimetry of a single dose of radium-223 in Japanese patients with …
(PK) and radiation dosimetry of a single dose of radium-223 in Japanese patients with …
[HTML][HTML] Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer
U Anido-Herranz, O Fernandez-Calvo… - Frontiers in …, 2024 - ncbi.nlm.nih.gov
Results A total of 145 patients were included; the median age was 73.97 years, and a
Gleason score of more than or equal to 7 in 61 (48%) patients; 73 (81%) had previously …
Gleason score of more than or equal to 7 in 61 (48%) patients; 73 (81%) had previously …
[HTML][HTML] Calculation of radium-223 and actinium-225 α-emitter radiopharmaceuticals dose rates in treatment of metastatic castration-resistant prostate cancer
A Abbasi, M Dadashpour… - Journal of Cancer …, 2021 - journals.lww.com
Aim of Study: There is limited information regarding the α-emitter radiopharmaceuticals dose
calculation used in the setting of men with prostate cancer (PCa). The present study …
calculation used in the setting of men with prostate cancer (PCa). The present study …
[HTML][HTML] Dosimetry-Based Consideration on Remission and Relapse after Therapy with 223Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone …
AM Mangano, M Pacilio, P Ialongo, A Semprebene… - Diagnostics, 2018 - mdpi.com
Here, we present the case of a 64-year-old male patient diagnosed with castration-resistant
prostate cancer (CRPC) with bone metastasis, treated with abiraterone prednisone …
prostate cancer (CRPC) with bone metastasis, treated with abiraterone prednisone …
Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?
I Gayed, V Salama, L Dawood, S Canfield… - Cancer Management …, 2018 - Taylor & Francis
Background Radium-223 dichloride (Ra-223 Xofigo) has recently been approved as an
addition to the host of available therapies in the USA as a treatment option for metastatic …
addition to the host of available therapies in the USA as a treatment option for metastatic …
Prostate cancer perspectives after chaarted: optimizing treatment sequence
SV Estévez, UA Herranz, OF Calvo, FJA Afonso… - Critical Reviews in …, 2016 - Elsevier
Prostate cancer is the most frequent cancer amongst men. Until recently, only two
therapeutic options, initial androgen-deprivation therapy in patients without castration …
therapeutic options, initial androgen-deprivation therapy in patients without castration …
[HTML][HTML] Response to 223Ra-dichloride in castration-resistant prostate cancer with bone metastasis: A case report
ME Cabrera, PM Rey, I Carrió… - Oncology …, 2016 - spandidos-publications.com
Painful bone metastases are common in prostate cancer, with current treatments including
non-steroidal analgesics and opiates, surgery, external beam radiotherapy and bone …
non-steroidal analgesics and opiates, surgery, external beam radiotherapy and bone …
[PDF][PDF] 223Ra-dichloride in castration-resistant prostate cancer (CRPC) with bone metastases: a still unexplored resource
L Mango - Oncol Res Rev, 2018 - researchgate.net
Metastatic skeletal disease is the cause of considerable morbidity in patients with advanced
Castration-Resistant Prostate Cancer (CRPC). It is considered that bone metastasis is the …
Castration-Resistant Prostate Cancer (CRPC). It is considered that bone metastasis is the …
[PDF][PDF] Kezelési stratégiák előrehaladott prosztatadaganatban
K Zsófia, B Krisztina, G Lajos, N Hajnalka - Magyar Onkológia, 2015 - huon.hu
A prosztatadaganat kezelésében az utóbbi évtized jelentős fejlődést eredményezett,
javultak a daganat felismerésének lehetőségei azáltal, hogy pontosabb diagnosztikai …
javultak a daganat felismerésének lehetőségei azáltal, hogy pontosabb diagnosztikai …